Trials / Completed
CompletedNCT02183168
Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
A Randomized, Open Label, 3-arm Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 192 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with Indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Meloxicam suppository | |
| DRUG | Meloxicam tablet | |
| DRUG | Indomethacin |
Timeline
- Start date
- 2001-07-01
- Primary completion
- 2002-05-01
- First posted
- 2014-07-08
- Last updated
- 2023-11-24
Source: ClinicalTrials.gov record NCT02183168. Inclusion in this directory is not an endorsement.